Fineline Cube

Follow:
14422 Articles
Changchun High‑Tech Secures NMPA Approval for GenSci139 Bispecific ADC in Advanced Solid Tumors
CompanyDrug

Changchun High‑Tech Secures NMPA Approval for GenSci139 Bispecific ADC in Advanced Solid Tumors

Salubris Shares Promising JK06 ADC Results from ESMO 2025 Clinical Presentation
CompanyDrug

Salubris Shares Promising JK06 ADC Results from ESMO 2025 Clinical Presentation

Advaccine Biotechnology Announces Private Placement of Up to 2.2 Million Shares to Raise RMB 300 Million for Microneedle & Vaccine Development
CompanyDeals

Advaccine Biotechnology Announces Private Placement of Up to 2.2 Million Shares to Raise RMB 300 Million for Microneedle & Vaccine Development

Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC
CompanyDrug

Summit Therapeutics Plans U.S. FDA BLA Submission for Ivonescimab + Chemotherapy in EGFR‑Mutated NSCLC

Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108
CompanyDeals

Samsung Bioepis Announces Global ADC Collaboration with Phrontline Biopharma to Advance TJ108

Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors
CompanyDrug

Shanghai Henlius Biotech Secures FDA Orphan Drug Designation for HLX43 in Thymic Epithelial Tumors

CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer
CompanyDrug

CARsgen Announces Promising Phase Ib Results for Satricabtagene Autoleucel Injection in Post‑Surgery Pancreatic Cancer

CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer
CompanyDrug

CSPC Pharmaceutical Secures Breakthrough Therapy Designation for JSKN003 in HER2‑Positive Colorectal Cancer

Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC
CompanyDrug

Akeso Announces Landmark Phase III Results for IVONESCIMAB in First‑Line Sq‑NSCLC

Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion
CompanyDrug

Wuhan YZY Biopharma Announces Interim Phase II Results for M701 in Malignant Pleural Effusion

China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply
CompanyDeals

China Isotope & Radiation Corp. Signs MoU With Brazil’s CNEN for Long‑Term Isotope Supply

Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares
CompanyDeals

Wuhan Healthgen Announces STAR Market IPO of ORYZOGEN Shares